Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KAINAIR vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Kainair is a selective agonist for kainate receptors, which are ionotropic glutamate receptors. It depolarizes neurons by increasing sodium and calcium conductance, leading to excitatory neurotransmission and neurotoxicity at high doses.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Refractory partial-onset seizures (adjunctive therapy),Off-label: Research tool for excitotoxicity studies
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
25 mg subcutaneously three times daily.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
3-5 hours, prolonging in renal impairment (up to 12-18 hours in GFR <30 m L/min).
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Primarily metabolized by CYP3A4 and CYP2C9 isoenzymes. Undergoes hydrolysis to inactive metabolites.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Primarily renal (approximately 90% unchanged drug within 24 hours), with minor biliary/fecal elimination (<10%).
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
92-98% bound, primarily to α1-acid glycoprotein.
65% bound to albumin
0.3-0.5 L/kg, indicating limited extravascular distribution.
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Intravenous 100%; intramuscular 65-75%; oral <5% due to extensive first-pass metabolism.
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
e GFR 30-89 m L/min: No adjustment. e GFR <30 m L/min: Not recommended.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
Child-Pugh A or B: No adjustment. Child-Pugh C: Contraindicated.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
Not approved for use in pediatric patients.
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
No specific dose adjustment; use with caution due to potential for altered clearance.
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
None.
No FDA black box warning.
Risk of neurotoxicity at high doses or rapid infusion,Can worsen seizure control in some epilepsy syndromes,Monitor liver function due to CYP metabolism,May cause dizziness, ataxia, and cognitive impairment
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Hypersensitivity to kainate receptor agonists,Severe hepatic impairment,Status epilepticus (non-approved indication)
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
No specific food interactions, but alcohol consumption increases risk of gastrointestinal bleeding. Maintain adequate hydration to reduce renal toxicity.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
Kainair (approval pending) is an adenosine receptor antagonist. Data insufficient. First trimester: theoretical risk based on animal studies showing dose-dependent embryotoxicity at supraclinical doses (reduced fetal weight, increased resorptions). Second/third trimester: no human data; may cause fetal tachycardia due to adenosine receptor blockade. Avoid use unless potential benefit outweighs risk.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
No data on excretion in human milk. M/P ratio unknown. Due to small molecular weight, possible transfer to infant. Risk of infant CNS stimulation and tachycardia. Avoid breastfeeding during therapy and for at least 5 half-lives after last dose.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
No established dose adjustments for pregnancy. Increased plasma volume and renal clearance in pregnancy may reduce drug exposure, potentially requiring higher doses, but no evidence exists. Use lowest effective dose with careful monitoring of maternal and fetal response. Avoid in third trimester due to risk of fetal tachycardia.
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
KAINAIR (ketorolac tromethamine) is an NSAID for short-term management of moderate to severe acute pain, not to exceed 5 days. Monitor renal function, especially in elderly, dehydrated, or on diuretics. Contraindicated in peptic ulcer disease, bleeding disorders, and renal impairment. Use lowest effective dose; co-administration with other NSAIDs or aspirin increases bleeding risk. Intramuscular injection: give deeply; do not use epidural or intrathecal route due to neurotoxicity.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Take this medication exactly as prescribed for the shortest duration necessary, usually no more than 5 days.,Avoid taking other NSAIDs (e.g., ibuprofen, naproxen) or aspirin while using this drug.,Report any signs of gastrointestinal bleeding (black stools, vomiting blood), easy bruising, or kidney problems (changes in urination, swelling) immediately.,This drug may cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Do not drink alcohol while taking this medication, as it increases the risk of stomach bleeding.,If you are pregnant, especially in the third trimester, do not use; avoid if breastfeeding.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KAINAIR vs AEROLATE, answered by our medical review team.
KAINAIR is a Bronchodilator that works by Kainair is a selective agonist for kainate receptors, which are ionotropic glutamate receptors. It depolarizes neurons by increasing sodium and calcium conductance, leading to excitatory neurotransmission and neurotoxicity at high doses.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KAINAIR and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KAINAIR is: 25 mg subcutaneously three times daily.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KAINAIR and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KAINAIR is classified as Category C. Kainair (approval pending) is an adenosine receptor antagonist. Data insufficient. First trimester: theoretical risk based on animal studies showing dose-dependent embryotoxicity a. AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.